

ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". The complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name)
William
2. Surname (Last Name)
Sandborn
3. Effective Date (07-August-2008)
13-January-2015
4. Are you the corresponding author? Yes No
5. Manuscript Title
2014-2015 ECCO Annual Disclosure of potential conflicts of interest
6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. **If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.**

The Work Under Consideration for Publication						
Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
1. Grant	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Receptos		X
						ADD
2. Consulting fee or honorarium	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Receptos		X
						ADD
3. Support for travel to meetings for the study or other purposes	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Receptos		X
						ADD
4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
5. Payment for writing or reviewing the manuscript	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
6. Provision of writing assistance, medicines, equipment, or administrative support	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Receptos		X

ICMJE Form for Disclosure of Potential Conflicts of Interest

The Work Under Consideration for Publication						
Type	No	Money Paid to You	Money to Your Institution*	Name of Entity	Comments**	
7. Other	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			ADD
						X
						ADD

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3.

Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. **If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.**

Relevant financial activities outside the submitted work						
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
1. Board membership	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Abbott Laboratories		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	ActoGeniX NV		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	AGI Therapeutics, Inc.		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Alba Therapeutics Corporation		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Albireo		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Alfa Wasserman		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Amgen		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	AM-Pharma BV		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Anaphore		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Astellas Pharma		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Athersys, Inc.		X

ICMJE Form for Disclosure of Potential Conflicts of Interest

Relevant financial activities outside the submitted work						
Type of Relationship (in alphabetical order)	No	Money Paid to You	Money to Your Institution*	Entity	Comments	
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Atlantic Healthcare Limited		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Axcan Pharma (now Aptalis)		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	BioBalance Corporation		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Boehringer-Ingelheim Inc		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Bristol Meyers Squibb		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Celegene		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Celek Pharmaceuticals		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Cellerix SL		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Cerimon Pharmaceuticals		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	ChemoCentryx		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	CoMentis		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Cosmo Technologies		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Coronado Biosciences		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Cytokine Pharmasciences		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eagle Pharmaceuticals		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eisai Medical Research Inc.		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Elan Pharmaceuticals		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	EnGene, Inc.		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Eli Lilly		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Enteromedics		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Exagen Diagnostics, Inc.		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ferring Pharmaceuticals		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Flexion Therapeutics, Inc.		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Funxional Therapeutics Limited		×
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Genzyme Corporation		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Genentech (now Roche)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Gilead Sciences	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Given Imaging	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Glaxo Smith Kline	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Human Genome Sciences	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Ironwood Pharmaceuticals (previously Microbia Inc.)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Janssen (previously Centocor)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	KaloBios Pharmaceuticals, Inc.	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lexicon Pharmaceuticals	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Lycera Corporation	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Meda Pharmaceuticals (previously Alaven Pharmaceuticals)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Merck Research Laboratories	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	MerckSerono	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Millennium Pharmaceuticals (subsequently merged with Takeda)	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Nisshin Kyorin Pharmaceuticals Co., Ltd.	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Novo Nordisk A/S	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	NPS Pharmaceuticals	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Optimer Pharmaceuticals	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Orexigen Therapeutics, Inc.	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	PDL Biopharma	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Pfizer	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	Procter and Gamble	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Prometheus Laboratories	<input type="checkbox"/>	<input checked="" type="checkbox"/>
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	ProtAb Limited	<input type="checkbox"/>	<input checked="" type="checkbox"/>

ICMJE Form for Disclosure of Potential Conflicts of Interest

2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Purgenesis Technologies, Inc.		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Relypsa, Inc.		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Salient Pharmaceuticals		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Salix Pharmaceuticals, Inc.		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Santarus		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Schering Plough Corporation (acquired by Merck)		X
2. Consultancy	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Shire Pharmaceuticals		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Sigmoid Pharma Limited		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Sirtris Pharmaceuticals, Inc. (a GSK company)		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	S.L.A. Pharma (UK) Limited		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Targacept		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Teva Pharmaceuticals		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Therakos		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Tillotts Pharma AG (acquired by Zeria Pharmaceutical Co., Ltd)		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	TxCell SA		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	UCB Pharma		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Viamet Pharmaceuticals		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Vascular Biogenics Limited (VBL)		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Warner Chilcott UK Limited		X
2. Consultancy	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Wyeth (now Pfizer)		X
						ADD
3. Employment	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
4. Expert testimony	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Dickinson, Prud'Homme, Adams & Ingram	Legal testimony regarding infliximab	X
						ADD
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Abbott Laboratories		X

ICMJE Form for Disclosure of Potential Conflicts of Interest

5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Bristol Meyers Squibb		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Genentech		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Glaxo Smith Kline		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Janssen (previously Centocor)		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Millennium Pharmaceuticals (now Takeda)		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Novartis		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Pfizer		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Procter and Gamble Pharmaceuticals		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Shire Pharmaceuticals		×
5. Grants/grants pending	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	UCB Pharma		×
						ADD
6. Payment for lectures including service on speakers bureaus	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Abbott Laboratories		×
6. Payment for lectures including service on speakers bureaus	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Bristol Meyers Squibb		×
6. Payment for lectures including service on speakers bureaus	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Janssen (previously Centocor)		×
						ADD
7. Payment for manuscript preparation	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			×
						ADD
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Use of topical azathioprine to treat inflammatory bowel disorders. United States patent number: 5,691,343. Date of patent: November 25, 1997.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J. Colonic delivery of nicotine to treat inflammatory bowel disease. South African patent number: 97/1020. Date of patent: January 28, 1998.		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Use of azathioprine to treat Crohn's disease. United States patent number: 5,733,915. Date of patent: March 31, 1998.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J. Colonic delivery of nicotine to treat inflammatory bowel disease. United States patent number: 5,846,983. Date of patent: December 8, 1998.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Azathioprine compositions for colonic administration. New Zealand patent number: 306062. Date of Patent: February 11, 1999.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Azathioprine compositions for colonic administration. Singapore patent number: 45647. Date of Patent: March 14, 1999.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J, Rhodes P, Evans BK. Colonic delivery of nicotine to treat inflammatory bowel disease. United States patent number: 5,889,028. Date of patent: March 30, 1999.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Topical formulations of azathioprine to treat inflammatory bowel disorders. United States patent number: 5,905,081. Date of Patent: May 18, 1999.		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Azathioprine compositions for colonic administration. Australia patent number: 707168. Date of Patent: October 14, 1999.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J, Evans BK. Intestinal absorption of nicotine to treat nicotine responsive conditions. Australia patent number: 718052. Date of patent: July 20, 2000.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J. Colonic delivery of nicotine to treat inflammatory bowel disease. United States patent number: 6,166,044. Date of patent: December 26, 2000.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Use of topical azathioprine and thioguanine to treat colorectal adenomas. United States patent number: 6,166,024. Date of patent: December 26, 2000.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Rhodes J, Evans BK, Rhodes P, Sandborn WJ. Intestinal absorption of nicotine to treat nicotine responsive conditions. United States patent number: 6,238,689. Date of patent: May 29, 2001.		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn, WJ. Azathioprine compositions for colonic administration. Czech Republic patent number: 290428. Date of patent: May 27, 2002.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn, WJ, Rhodes J. Colonic delivery of nicotine to treat IBD. Mexico patent number: 209636. Date of Patent August 12, 2002.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ. Enema and enterically-coated oral dosage forms of azathioprine. United States Patent No.: 6,432,967. Date of patent: August 13, 2002.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J. Colonic delivery of nicotine to treat nicotine responsive conditions. Europe patent number: 0954337. Date of patent: November 2, 2002.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J, Rhodes P, Evans BK. Colonic delivery of nicotine to treat IBD. Europe patent number: 893998. Date of patent: April 15, 2003.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J, Rhodes P, Evans BK. Colonic delivery of nicotine to treat inflammatory bowel disease. Hong Kong patent number: HK1019043. Date of patent: August 1, 2003.		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn WJ, Rhodes J, Rhodes P, Evans BK. Colonic delivery of nicotine to treat IBD. China patent number: ZL97192177. Date of patent: November 12, 2003.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sandborn W, Rhodes J, Rhodes P, Evans B. Colonic delivery of nicotine to treat inflammatory bowel disease. Czech patent number: 293616. Patent date: 2004.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Rhodes J, Sandborn WJ, Rhodes P, Evans BK. Colonic deliver of nicotine to treat inflammatory bowel disease. Canada patent number: 2,246,235. Patent date: 2007.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Sachetto JP, Sandborn WJ, Tremaine WJ. Pharmaceutical composition for the treatment of inflammatory bowel disease. United States patent number: 7341741. Patent date 2008.		×
8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Rhodes J, Evans BK, Rhodes P, Sandborn WJ. Intestinal absorption of nicotine to treat nicotine responsive conditions. Canadian patent number: 2,260,909. Patent date 2008.		×

ICMJE Form for Disclosure of Potential Conflicts of Interest

8. Patents (planned, pending or issued)	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Levy MJ, Camilleri ML, Murray JA, Sandborn WJ. Obesity treatment and device. United States patent number: 7,803,195 B2. Date of patent September 28, 2010.		X
						ADD
9. Royalties	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
10. Payment for development of educational presentations	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
11. Stock/stock options	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Enteromedics		X
						ADD
12. Travel/accommodations/meeting expenses unrelated to activities listed**	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD
13. Other (err on the side of full disclosure)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>			X
						ADD

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4.

Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest
- Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE

ICMJE Form for Disclosure of Potential Conflicts of Interest

Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.